|| List of recent Polypeptide-related patents
| Therapeutic methods for type i diabetes|
The invention relates to the treatment and prevention of type i diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of langerhans) by inhibition of jnk2, selective inhibition of jnk2, or inhibition of the expression of the mapk9 gene or gene product.
| New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids|
This invention relates to a conjugated molecule comprising a peptide derived from the cd4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide.
| Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy|
The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for kdr or vegf/kdr complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding kdr or vegf/kdr complex with high affinity (e.g., having a kd<1 μm), and dimer and multimeric constructs comprising these polypeptides..
| Soluble hybrid fcgamma receptors and related methods|
Disclosed are soluble hybrid fcγ receptor (fcγr) polypeptide compositions and related methods of using such polypeptides to treat igg-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid fcγr polypeptides..
| Polypeptide compounds for inhibiting angiogenesis and tumor growth|
In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting ephrin b2 or ephb4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases..
| Engineered polypeptides having enhanced duration of action|
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides.
| Methods and systems for adenovirus interaction with desmoglein 2 (dsg2)|
The present invention provides compositions, compounds, and methods relating to recombinant adenoviral-based polypeptides for treating disorders associated with epithelial tissues.. .
| Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages|
The present invention relates to a system and method for controlling peptide display valency on virus-like particles (vlps), especially including ms2 or pp7 vlps. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single rna.
| Polypeptides having xylanase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having xylanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
| Glycosyl hydrolase enzymes and uses thereof for biomass hydrolysis|
The present invention relates to compositions that can be used in hydrolyzing biomass such as compositions comprising a polypeptide having glycosyl hydrolase (gh) family 61/endoglucanase activity and/or a β-glucosidase polypeptide, methods for hydrolyzing biomass material, and methods for using such compositions.. .
| Protein production in microorganisms of the phylum labyrinthulomycota|
The present invention relates to recombinant cells and microorganisms of the phylum labyrinthulomycota and their use in heterologous protein production. Novel promoter, terminator, and signal sequences for efficient production and, optionally, secretion of polypeptides from recombinant host cells and microorganisms are also encompassed by the present invention..
| Selection of host cells expressing protein at high levels|
Described is a dna molecule comprising an open reading frame sequence encoding a selectable marker polypeptide, wherein the dna molecule in the coding strand comprises a translation start sequence for the selectable marker polypeptide having a gtg or ttg start codon, and wherein the orf sequence that encodes the selectable marker protein has been mutated to replace at least half of its cpg dinucleotides as compared to the native orf sequence that encodes the selectable marker protein. Further provided are such dna molecules wherein the orf sequence that encodes a selectable marker polypeptide is part of a multicistronic transcription unit that further comprises an open reading frame sequence encoding a polypeptide of interest.
| Polypeptides having carboxypeptidase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having carboxypeptidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
| Methods for production and purification of polypeptides|
The present invention relates to a method for production and purification of polypeptides. In particular, the present invention relates to a fusion protein comprising a solubility-enhancing peptide tag moiety, a self-aggregating peptide moiety and a moiety of target peptide and to a method for production and purification of target peptides through expressing said fusion protein..
| Novel genes causing hereditary kidney disease or malformation of the urinary tract|
Isolated nucleotides encoding polypeptides with mutations leading to amino acid substitutions linked to hereditary kidney disease or malformation of the urinary tract are provided herein. Constructs, cells, probes and inhibitory molecules comprising these mutations are also provided and may be used in screening assays for candidate agents to treat or reverse these diseases or alternatively to provide diagnostic tests.
| Frizzled-binding agents and uses thereof|
Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified.
| Apoptosis-inducing molecules and uses therefor|
This invention relates generally to methods and agents for modulating adiposity-related conditions. More particularly, the present invention relates to the use of trail death receptor agonists, including nucleic acids such as trail polynucleotides, peptides and polypeptides including trail polypeptides, trail dr agonist antigen-binding molecules, trail dr peptide agonists as well as small molecule trail dr agonists in compositions and methods for treating or preventing adiposity-related conditions such as obesity, diabetes mellitus and metabolic syndrome..
| Use of mesenchymal stem cells for the improvement of affective and cognitive function|
Disclosed is the use of mesenchymal stem cells (mscs) and in particular mscs pretreated with pituitary adenylate cyclase-activating polypeptide (pacap) or analogs and fragments of pacap, for treatment of neurodegenerative and psychiatric diseases, and for the improvement of affective and cognitive function in a normal individual or in an individual suffering from a neurodegenerative or neuropsychiatric disease.. .
|Polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase activity and beta-xylosidase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Genetically encoded calcium indicators and methods of use|
Genetically encoded calcium indicator (geci) polypeptides and the nucleic acid molecules encoding such polypeptides are provided. In addition, methods of using such nucleic acids and polypeptides in methods of screening for agonists or antagonists of g-protein coupled receptor (gpcr) or ion channels and methods of monitoring neural activity also are provided..
|Rational design of components of the oligo-saccharyltransferase-catalysed asparagine-linked glycosylation|
The present invention is directed to methods for identifying or designing (a) a potential oligosaccharide donor, (b) a potential oligosaccharyltransferase (ost), (c) a potential consensus sequence motif polypeptide, and/or (d) a potential glycosylation inhibitor for use in the oligosaccharyltransferase (ost)-catalysed asparagine-linked (“n-linked”) glycosylation, comprising the steps of generating a three-dimensional model of the catalytic domain and/or the polypeptide binding site of the oligosaccharyltransferase (ost) of campylobacter lari, and designing or selecting a potential component selected from (a) to (d) which optimizes the stereo chemical complementarity of said three-dimensional model(s) and the potential component.. .
|Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides|
Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one aromatic amine group.
|Novel immunoglobulin-binding polypeptide|
An object of the present invention is to provide novel polypeptides that are capable of binding to an immunoglobulin and have high stability against alkali. The present invention relates to proteins having the amino acid sequence of seq id no:1 or 2..
|Liver cancer diagnosis marker and use thereof|
A marker for the detection of liver cancer and application of the marker thereof. The application includes use of cytochrome p450 family 17 subfamily a polypeptide 1 (cyp17a1 protein) in the preparation of diagnostic reagents or kits for the detection of liver cancer kit.
|Fluorescent detection of in vitro translated protein on a solid surface|
Disclosed herein are methods and kits useful in the detection of protein folding and in the identification of compounds that promote proper protein folding. In one example approach, fluorophores and a protein tag are incorporated into a nascent polypeptide within a ribosome-nascent-chain complex during cell free translation and the resulting labeled ribosome-nascent-chain complex is conjugated to a solid surface via the tag.
|Antibody polypeptides that antagonize cd40l|
Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
|Compositions and methods for enhancing production of a biological product|
The invention provides compositions and methods for producing a biological product from a host cell. In various embodiments, the biological product is a polypeptide, a metabolite, a nutraceutical, a chemical intermediate, a biofuel, a food additive, or an antibiotic.
|Composites containing polypeptides attached to polysaccharides and molecules|
This document provides methods and materials related to composites or coatings containing polypeptides attached to polysaccharides and/or molecules. For example, methods and materials related to composites or coatings containing polypeptides (e.g., casein polypeptides) attached to polysaccharides (e.g., cellulose) and/or molecules (e.g., calcium containing molecules such as calcium phosphate and calcium carbonate and/or polyesters such as polylactic acid and polyhydroxybutyrate) are provided.
|Asparaginase enzyme variants and uses thereof|
The present invention relates to newly identified asparaginase polypeptide variants of seq id no: 3 and to polynucleotide sequences that encode such novel asparaginase variants. Furthermore the invention relates to the use of these novel asparaginase variants in industrial processes..
The present invention provides a therapeutic or improving agent for a lifestyle-related disease, containing an expression vector encoding a chimeric hepatitis b virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of the lifestyle-related disease-related factor, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis b virus core antigen polypeptide.. .
|Antibody polypeptides that antagonize cd40|
Antibody polypeptides that specifically bind a novel epitope of human cd40 are provided. The antibody polypeptides do not exhibit cd40 agonist activity.
|S. aureus polypeptide and antibodies|
The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.. .
|New dendritic cell co-stimulatory molecules|
A novel costimulatory protein molecule, b7-dc, which is a member of the b7 family, is described as is dna coding therefor and expression vectors comprising this dna. B7-dc protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing b7-dc are useful in vaccine compositions and methods.
The present invention relates to recombinant ace2 polypeptide, where the ace2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.
|Biotherapy for pain|
The present invention is directed to analgesic clostridial neurotoxin derivatives comprising polypeptides having a long-lasting snare protein-selective endopeptidase activity. These derivatives selectively bind to and are internalized by non-neuronal cells secreting cytokines or sensory neurons in preference to motor neurons or autonomic neurons.
|Novel superactive il-33 fragments, and uses thereof|
The present invention discloses novel active polypeptide fragments of human il-33 corresponding to natural forms generated by the proteases of human neutrophils (cathepsin g, elastase 2, proteinase 3), as well as the use thereof as a drug, in particular for the treatment of infectious diseases, inflammatory diseases, atherosclerosis, cardiovascular diseases, obesity, or cancer.. .
|Methods for production of proteins|
The current invention provides methods for producing a polypeptide as inclusion bodies in bacterial host cells. The present methods are carried out by forming a gene construct comprising the genetic sequence encoding a polypeptide operatively linked to that of an inclusion partner protein, such that host cells comprising the gene construct produce the polypeptide as intracellular inclusion bodies thereby facilitating rapid isolation and purification of recombinant proteins.
|Polypeptides having endoglucanase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Plants having enhanced yield-related traits and a method for making the same|
The present invention relates generally to the field of molecular biology and concerns a method for enhancing various yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding a tcp1 or a tcp2 transcription factor, an epsin-like polypeptide, a trna delta(2)-isopentenylpyrophosphate transferase (ippt) polypeptide, or a short-root (shr) polypeptide. The present invention also concerns plants having modulated expression of a nucleic acid encoding a tcp1 or tcp2 polypeptide, an epsin-like polypeptide, a trna delta(2)-isopentenylpyrophosphate transferase (ippt) polypeptide, or a short-root (shr) polypeptide, which plants have enhanced yield-related traits relative to corresponding wild type plants or other control plants.
|Axmi232, axmi233, and axmi249 toxin genes and methods for their use|
Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided.
|Ssh-2 (slingshot-2) inhibitors and methods for making and using them|
In alternative embodiments, the invention provides compositions that inhibit the polypeptide ssh-2, or slingshot-2, a phosphatase enzyme that regulates actin filaments, and methods for making and using them, including methods comprising administering compositions of the invention to regulate or modify actin filament polymerization by inhibiting ssh-2, where in one embodiment compositions of the invention slow or inhibit f-actin depolymerization and severing. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit cell motility and/or internal remodeling.
|Mitrecin a polypeptide with antimicrobial activity|
The present invention provides a mitrecin a polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a mitrecin a polypeptide.
|Stromal antigen 2 (stag2) compositions and methods|
Compositions and methods related to stromal antigen 2 (stag2) and its role in diverse human cancers, including nucleic acids, polypeptides, vectors, cells and cell lines.. .
|Expression systems and methods of producing spider silk proteins|
An expression system, including a host cell, a synthetic spider silk polypeptide-encoding nucleotide sequence, at least one synthetic trna molecule-encoding nucleotide sequence or a synthetic serine hydroxymethyl transferase (shmt)-encoding nucleotide sequence.. .
|Modified human thymic stromal lymphopoietin|
Modified, furin resistant human tslp polypeptides and polynucleotides encoding the modified human tslp polypeptides are provided. Pharmaceutical compositions, b and t cell activation agents, assays and methods of use are also described..
|Prokaryotic rnai-like system and methods of use|
Provided herein are methods for inactivating a target polynucleotide. The methods use a psirna having a 5′ region and a 3′ region.
|Polypeptides having cellulolytic enhancing activity and nucleic acids encoding same|
The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides..
|Type ii restriction modification system methylation subunit of alicyclobacillus acidocaldarius|
Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from alicyclobacillus acidocaldarius are provided. Further provided are methods for modulating or altering recombination inside or outside of a cell using isolated and/or purified polypeptides and/or nucleic acid sequences from alicyclobacillus acidocaldarius..
|Polypeptides with ketol-acid reductoisomerase activity|
Polypeptides having ketol-acid reductoisomerase activity are provided. Also disclosed are recombinant host cells comprising isobutanol biosynthetic pathways employing such polypeptides.
|Variant sucrose transporter polypeptides that enable faster sucrose utilization in bacteria|
Variant sucrose transporter polypeptides that enable faster sucrose utilization in bacteria are described. Additionally, variant or recombinant bacteria comprising these variant sucrose transporter polypeptides, and methods of utilizing the bacteria to produce products such as glycerol and glycerol-derived products are provided..
|Polypeptides having endoglucanase activity and polynucleotides encoding same|
The present invention relates to isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
|Marker comprising anti-ck8/18 complex autoantibody and its use for diagnosing cancer|
The present invention relates to a cytokeratin 8/18 complex-specific autoantibody or a fragment comprising an antigen-binding site (paratope) thereof, the use thereof in the diagnosis of breast cancer, a polypeptide having an amino acid sequence of an epitope specifically binding to the autoantibody, a composition for diagnosing breast cancer comprising an agent capable of measuring an expression level of the autoantibody or the fragment comprising an antigen-binding site thereof, a hybridoma cell line producing the autoantibody, and a kit for diagnosing breast cancer comprising the composition of the present invention. Further, the present invention relates to a method for diagnosing breast cancer, comprising the step of detecting the cytokeratin 8/18 complex-specific autoantibody or the fragment comprising the antigen-binding site thereof using the composition of the present invention, and a method for screening a therapeutic agent for breast cancer using the autoantibody..
|Highly pure plasmid dna preparations|
The present disclosure generally relates to highly pure plasmid compositions having low, or undetectable, levels of colanic acid and other contaminants made by a process that includes the steps of obtaining a crude lysate of a plasmid dna from a bacteria that makes colanic acid; treating the partially purified or purified plasmid dna with a polypeptide that digests colanic acid under conditions that digest the colanic acid; and purifying the plasmid dna from the digested colanic acid and the colanic acid degrading enzyme by one or more chromatography steps.. .
|Immunogenic compositions and expression systems|
Immunogenic compositions and vaccines against plasmodial infection comprising an rh polypeptide or a fragment or variant thereof are disclosed. Also disclosed are rh5 polypeptides or fragments or variants thereof capable of binding cd147 and conferring protection against infection and/or disease caused by multiple plasmodial strains or plasmodial species, inhibitors of the interaction between rh5 and cd147 and methods for producing polypeptides in a mammalian expression system..
|Compositions and methods of enhancing immune responses|
Provided herein are salmonella enteritidis 13a strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against influenza a and methods of reducing morbidity associated with an influenza a infection.
|Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof|
Various aspects of the invention provide for capsids, parvovirus capsids, hybrid parvovirus capsids, parvovirus vectors, hybrid parvovirus vectors, hybrid parvovirus particles and parvovirus particles containing polypeptides in which the sequence ycdgfyacymdv (seq id no: 3) has been substituted into the vp2 loop of the b19 capsid protein. Polypeptides in which the sequence ycdgfyacymdv (seq id no: 3) has been substituted into the vp2 loop of the b19 capsid protein are also provided (e.g., seq id no: 2).
|Immunogenic compositions in particulate form and methods for producing the same|
The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumour origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient.
|Lutzomyia longipalpis polypeptides and methods of use|
Substantially purified salivary lu. Longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed.
|Deletion of the beta 20-21 loop in hiv gp120 exposes the cd4 binding site for improved antibody binding and antibody induction|
Disclosed herein are isolated immunogens including variant gp120 polypeptides. In an example, a variant gp120 polypeptide includes a deletion of at least 8 consecutive residues of the fourth conserved loop (c4) between residues 419 and 434 of gp120 according to hxb2 numbering.
|Modified chaperonin 10|
The present invention relates to isolated chaperonin 10 polypeptides possessing immunomodulatory activity, but lacking, or substantially lacking, protein folding activity.. .
|Fc-gamma-riib-specific fc antibody|
An objective of the present invention is to provide a polypeptide containing an fc region having maintained or decreased binding activities towards both allotypes of fcγriia, types h and r, and having enhanced fcγriib-binding activity in comparison with a parent polypeptide; a pharmaceutical composition containing the polypeptide; an agent for treating or preventing immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method for maintaining or decreasing binding activities towards both allotypes of fcγriia and enhancing the fcγriib-binding activity. Specifically, it is found that a polypeptide containing an antibody fc region that has an alteration of substituting pro at position 238 (eu numbering) with asp or leu at position 328 (eu numbering) with glu enhances fcγriib-binding activity, and maintains or decreases binding activities towards both allotypes of fcγriia, types h and r.
|Modulating bacterial mam polypeptides in pathogenic disease|
The disclosure relates to methods and compositions for preventing or inhibiting pathogenic bacterial infections in a subject caused by pathogenic bacteria expressing a multivalent adhesion molecule (mam) polypeptide by administering to a subject a composition comprising a mam polypeptide or a non-pathogenic bacterium expressing a mam polypeptide, or a combination thereof.. .
|Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement|
Recombinant polynucleotides useful for improvement of plants are provided. In particular, polynucleotide sequences are provided from plant sources.
|Plants having enhanced yield-related traits and method for making the same|
Provided is a method for enhancing yield-related traits in plants by increasing expression in plants of a nucleic acid encoding a low sulfur upregulated polypeptide (lsu). Also provided are plants having increased expressing of a nucleic encoding an lsu polypeptide, which have enhanced yield-related traits compared with control plants.
|Methods and compositions for increasing plant disease resistance and yield|
The present invention discloses novel plant homologs of the arabidopsis peptide atpep1. Atpep peptides in arabidopsis are involved in the amplification of defense pathways involved in innate immunity against microbial pathogens.
|Modulators of slc22a7|
The present invention is directed to the identification of modulators for slc22a7 transporter and therapeutic uses thereof. Hence, in one embodiment the present invention relates to a method for identifying and/or obtaining a compound capable of modulating glutamate transport, comprising contacting a test compound with a system for measuring those transport activity, which system comprises an slc22a7 polypeptide or a functional fragment thereof, and a substrate for measuring glutamate transport by the system; and detecting an altered level of the those transport activity of the slc22a7 polypeptide or functional fragment in the presence of the test compound compared to the described transport activity in the absence of the test compound and/or presence of a control..
|Photosynthetic organisms and compositions and methods of generating same|
An isolated polynucleotide is provided. The isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide of a type ii reaction center of a photosynthetic organism, the nucleic acid sequence being capable of imparting the type ii reaction center with an activity under a temperature range different than that of the type ii reaction center endogenous to the photosynthetic organism.
|Water-soluble polypeptides comprised of repeat modules, method for preparing the same and method for a target-specific polypeptide and analysis of biological activity thereof|
The present invention relates to a soluble polypeptide comprised of repeat modules. More particularly, the present invention relates to a soluble fusion polypeptide of the n-terminal domain of internalin and lrr (leucine rich repeat) family protein, a method for preparing the polypeptide, a vector comprising a nucleic acid sequence encoding the polypeptide, a host cell comprising the vector, a method for producing a solubility and folding-improved fusion polypeptide by expressing the vector in the host cell, and a method for improving the solubility and folding of the fusion polypeptide.
|Mucin 3 egf-like domains|
The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 egf like domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or nucleic acids..
|Complexation of metal ions with polypeptides|
Formulations and methods are provided for improving the stability upon exposure to aqueous media of polypeptides present in non-aqueous suspension vehicles. In particular aspects of the invention, formulations are provided that comprise a complex of a metal ion and a polypeptide suspended in a non-aqueous, biocompatible suspension vehicle.
|Chimeric neuregulins and method of making and use thereof|
Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first polypeptide; and a second moiety of at least 5 amino acids, wherein the second moiety is derived from a second polypeptide; wherein the first polypeptide is a neuregulin and the chimeric neuregulin exhibits an enhanced binding affinity to integrin, erb 3, or erb 4 comparing to that of the first neuregulin..
|Novel activin receptor and uses thereof|
The present invention provides novel activin iib5 receptor polypeptides capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides.
|Polymer-based sustained release device|
This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar..